RT Journal Article
T1 Validation of calprotectin as a novel biomarker for the diagnosis of pleural effusion: a multicentre trial
A1 Botana Rial, María Isabel
A1 Vázquez Iglesias, Lorena
A1 Casado Rey, Pedro
A1 Páez de la Cadena Tortosa, María
A1 Andrade Olivié, María Amalia
A1 Abal Arca, José
A1 García Nimo, Laura
A1 Ferreiro Fernández, Lucía
A1 Valdés Cuadrado, Luis
A1 San José, María Esther
A1 Rodríguez Berrocal, Francisco Javier
A1 Fernández Villar, Alberto
K1 2302.21 Biología Molecular
K1 2409 Genética
K1 32 Ciencias Médicas
K1 3207.13 Oncología
AB Discriminating between malignant pleural effusion (MPE) and benign pleural effusion (BPE) remains difficult. Thus, novel and efficient biomarkers are required for the diagnosis of pleural effusion (PE). The aim of this study was to validate calprotectin as a diagnostic biomarker of PE in clinical settings. A total of 425 patients were recruited, and the pleural fluid samples collected had BPE in 223 cases (53.7%) or MPE in 137 patients (33%). The samples were all analysed following the same previously validated clinical laboratory protocols and methodology. Calprotectin levels ranged from 772.48 to 3,163.8 ng/mL (median: 1,939 ng/mL) in MPE, and 3,216–24,000 ng/mL in BPE (median: 9,209 ng/mL; p < 0.01), with an area under the curve of 0.848 [95% CI: 0.810–0.886]. For a cut-off value of ≤ 6,233.2 ng/mL, we found 96% sensitivity and 60% specificity, with a negative and positive predictive value, and negative and  positive likelihood ratios of 96%, 57%, 0.06, and 2.4, respectively. Multivariate analysis showed that low calprotectin levels was a better discriminator of PE than any other variable [OR 28.76 (p < 0.0001)]. Our results confirm that calprotectin is a new and useful diagnostic biomarker in patients with PE of uncertain aetiology which has potential applications in clinical practice because it may be a good complement to cytological methods.
PB Scientific Reports
SN 20452322
YR 2020
FD 2020-03-30
LK http://hdl.handle.net/11093/2120
UL http://hdl.handle.net/11093/2120
LA eng
NO Scientific Reports, 10(1): 5679(2020)
NO Instituto de Salud Carlos III | Ref. PI13/01538
DS Investigo
RD 15-mar-2025